{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:40Z","timestamp":1788902020709,"version":"build-2803163510"},"reference-count":366,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001747","name":"Hong Kong Baptist University","doi-asserted-by":"publisher","award":["RC-IRMS\/13-14\/03"],"award-info":[{"award-number":["RC-IRMS\/13-14\/03"]}],"id":[{"id":"10.13039\/501100001747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02998-6","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:08:14Z","timestamp":1788858494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects"],"prefix":"10.1038","volume":"11","author":[{"given":"Rongjun","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-0494","authenticated-orcid":false,"given":"Aiping","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-5292","authenticated-orcid":false,"given":"Yuanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2998_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"Ca. Cancer J. Clin."},{"key":"2998_CR2","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125, 3356\u20133364 (2015).","journal-title":"J. Clin. Invest."},{"key":"2998_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2998_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208\u2013220 (2016).","journal-title":"Trends Immunol."},{"key":"2998_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He, S., Zheng, L. & Qi, C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol. Cancer 24, 5 (2025).","journal-title":"Mol. Cancer"},{"key":"2998_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR7","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1073\/pnas.75.10.5142","volume":"75","author":"JA Bennett","year":"1978","unstructured":"Bennett, J. A., Rao, V. S. & Mitchell, M. S. Systemic bacillus Calmette-Gu\u00e9rin (BCG) activates natural suppressor cells. Proc. Natl. Acad. Sci. 75, 5142\u20135144 (1978).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2998_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","volume":"67","author":"DI Gabrilovich","year":"2007","unstructured":"Gabrilovich, D. I. et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425 (2007).","journal-title":"Cancer Res."},{"key":"2998_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739\u2013752 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2998_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3\u20138 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Leader, A. M. & Merad, M. MDSC: Markers, development, states, and unaddressed complexity. Immunity 54, 875\u2013884 (2021).","journal-title":"Immunity"},{"key":"2998_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"H-R Jin","year":"2023","unstructured":"Jin, H.-R. et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J. Hematol. Oncol. 16, 103 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2998_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark. Res. 12, 96 (2024).","journal-title":"Biomark. Res."},{"key":"2998_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-physiol-050824-111031","volume":"88","author":"A Grover","year":"2026","unstructured":"Grover, A., Tcyganov, E. N. & Gabrilovich, D. I. Myeloid cell reprogramming and immune suppression. Annu. Rev. Physiol. 88, 437\u2013457 (2026).","journal-title":"Annu. Rev. Physiol."},{"key":"2998_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101380","volume":"5","author":"F Pettinella","year":"2024","unstructured":"Pettinella, F. et al. Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell Rep. Med. 5, 101380 (2024).","journal-title":"Cell Rep. Med."},{"key":"2998_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","volume":"5","author":"H Alshetaiwi","year":"2020","unstructured":"Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).","journal-title":"Sci. Immunol."},{"key":"2998_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"2998_CR19","doi-asserted-by":"publisher","first-page":"aaf8943","DOI":"10.1126\/sciimmunol.aaf8943","volume":"1","author":"T Condamine","year":"2016","unstructured":"Condamine, T. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1, aaf8943 (2016).","journal-title":"Sci. Immunol."},{"key":"2998_CR20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1084\/jem.20080132","volume":"205","author":"P Cheng","year":"2008","unstructured":"Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235\u20132249 (2008).","journal-title":"J. Exp. Med."},{"key":"2998_CR21","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. S100A8\/A9 in inflammation. Front. Immunol. 9, 1298 (2018).","journal-title":"Front. Immunol."},{"key":"2998_CR22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines, J. L. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74, 1924\u20131932 (2014).","journal-title":"Cancer Res"},{"key":"2998_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.CIR-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng, J. et al. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol. Res. 7, 1079\u20131090 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113661","volume":"43","author":"K Zhang","year":"2024","unstructured":"Zhang, K. et al. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Rep. 43, 113661 (2024).","journal-title":"Cell Rep."},{"key":"2998_CR25","doi-asserted-by":"publisher","first-page":"e70231","DOI":"10.1002\/mco2.70231","volume":"6","author":"T Hu","year":"2025","unstructured":"Hu, T. et al. Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations. MedComm 6, e70231 (2025).","journal-title":"MedComm"},{"key":"2998_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111128","volume":"125","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma. Int. Immunopharmacol. 125, 111128 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2998_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/neuonc\/now034","volume":"18","author":"PR Gielen","year":"2016","unstructured":"Gielen, P. R. et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function. Neuro Oncol. 18, 1253\u20131264 (2016).","journal-title":"Neuro Oncol."},{"key":"2998_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215598","volume":"532","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer. Cancer Lett. 532, 215598 (2022).","journal-title":"Cancer Lett."},{"key":"2998_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-023-01337-3","volume":"8","author":"R Zhang","year":"2023","unstructured":"Zhang, R. et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct. Target. Ther. 8, 97 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR30","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","volume":"23","author":"YG Najjar","year":"2017","unstructured":"Najjar, Y. G. et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1\u03b2, IL8, CXCL5, and mip-1\u03b1. Clin. Cancer Res. 23, 2346\u20132355 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm5214","volume":"387","author":"C Jackson","year":"2025","unstructured":"Jackson, C. et al. Distinct myeloid-derived suppressor cell populations in human glioblastoma. Science 387, eabm5214 (2025).","journal-title":"Science"},{"key":"2998_CR32","doi-asserted-by":"publisher","first-page":"e1001162","DOI":"10.1371\/journal.pbio.1001162","volume":"9","author":"B Toh","year":"2011","unstructured":"Toh, B. et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 9, e1001162 (2011).","journal-title":"PLoS Biol."},{"key":"2998_CR33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317\u20131334.e10 (2019).","journal-title":"Immunity"},{"key":"2998_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell 16, 183\u2013194 (2009).","journal-title":"Cancer Cell"},{"key":"2998_CR35","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cac2.70027","volume":"45","author":"W Cai","year":"2025","unstructured":"Cai, W. et al. Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor. Cancer Commun. 45, 888\u2013913 (2025).","journal-title":"Cancer Commun."},{"key":"2998_CR36","doi-asserted-by":"publisher","first-page":"840029","DOI":"10.3389\/fimmu.2022.840029","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang, S., Liu, G., Li, Y. & Pan, Y. Metabolic reprogramming induces macrophage polarization in the tumor microenvironment. Front. Immunol. 13, 840029 (2022).","journal-title":"Front. Immunol."},{"key":"2998_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2492\/inflammregen.34.124","volume":"34","author":"W Fujii","year":"2014","unstructured":"Fujii, W., Ashihara, E. & Kawahito, Y. Myeloid-derived suppressor cells in autoimmune diseases. Inflamm. Regen. 34, 124\u2013128 (2014).","journal-title":"Inflamm. Regen."},{"key":"2998_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62874-9","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun, Y. et al. CCR7+ dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse. Nat. Commun. 16, 7581 (2025).","journal-title":"Nat. Commun."},{"key":"2998_CR39","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","volume":"35","author":"G Ferrer","year":"2021","unstructured":"Ferrer, G. et al. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia 35, 3163\u20133175 (2021).","journal-title":"Leukemia"},{"key":"2998_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","volume":"40","author":"P Wu","year":"2014","unstructured":"Wu, P. et al. \u03b3\u03b4T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785\u2013800 (2014).","journal-title":"Immunity"},{"key":"2998_CR41","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jid.2016.02.816","volume":"136","author":"LY Cao","year":"2016","unstructured":"Cao, L. Y. et al. Myeloid-derived suppressor cells in psoriasis are an expanded population exhibiting diverse T-cell\u2013suppressor mechanisms. J. Invest. Dermatol. 136, 1801\u20131810 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"2998_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaut.2017.07.010","volume":"85","author":"A Sica","year":"2017","unstructured":"Sica, A. & Massarotti, M. Myeloid suppressor cells in cancer and autoimmunity. J. Autoimmun. 85, 117\u2013125 (2017).","journal-title":"J. Autoimmun."},{"key":"2998_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1183\/13993003.01572-2015","volume":"47","author":"S Kolahian","year":"2016","unstructured":"Kolahian, S. et al. The emerging role of myeloid-derived suppressor cells in lung diseases. Eur. Respir. J. 47, 967\u2013977 (2016).","journal-title":"Eur. Respir. J."},{"key":"2998_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/imm.13040","volume":"156","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Polymorphonuclear myeloid-derived suppressor cells attenuate allergic airway inflammation by negatively regulating group 2 innate lymphoid cells. Immunology 156, 402\u2013412 (2019).","journal-title":"Immunology"},{"key":"2998_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/annrheumdis-2014-205508","volume":"75","author":"C Guo","year":"2016","unstructured":"Guo, C. et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann. Rheum. Dis. 75, 278\u2013285 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2998_CR46","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41423-023-01004-1","volume":"20","author":"K Rui","year":"2023","unstructured":"Rui, K., Peng, N., Xiao, F., Lu, L. & Tian, J. New insights into the functions of MDSCs in autoimmune pathogenesis. Cell. Mol. Immunol. 20, 548\u2013550 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR47","doi-asserted-by":"publisher","first-page":"331ra40","DOI":"10.1126\/scitranslmed.aae0482","volume":"8","author":"H Wu","year":"2016","unstructured":"Wu, H. et al. Arginase-1\u2013dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci. Transl. Med. 8, 331ra40 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2998_CR48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ymthe.2022.10.013","volume":"31","author":"C Hu","year":"2023","unstructured":"Hu, C. et al. Polyamines from myeloid-derived suppressor cells promote Th17 polarization and disease progression. Mol. Ther. 31, 569\u2013584 (2023).","journal-title":"Mol. Ther."},{"key":"2998_CR49","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ccell.2023.02.004","volume":"41","author":"N Bancaro","year":"2023","unstructured":"Bancaro, N. et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell 41, 602\u2013619.e11 (2023).","journal-title":"Cancer Cell"},{"key":"2998_CR50","doi-asserted-by":"publisher","first-page":"933847","DOI":"10.3389\/fimmu.2022.933847","volume":"13","author":"C Van Geffen","year":"2022","unstructured":"Van Geffen, C., Heiss, C., Dei\u00dfler, A. & Kolahian, S. Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation. Front. Immunol. 13, 933847 (2022).","journal-title":"Front. Immunol."},{"key":"2998_CR51","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ymthe.2024.04.026","volume":"32","author":"HJ Lee","year":"2024","unstructured":"Lee, H. J., Choi, Y. R., Ko, J. H., Ryu, J. S. & Oh, J. Y. Defining mesenchymal stem\/stromal cell-induced myeloid-derived suppressor cells using single-cell transcriptomics. Mol. Ther. 32, 1970\u20131983 (2024).","journal-title":"Mol. Ther."},{"key":"2998_CR52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","volume":"24","author":"L Akkari","year":"2024","unstructured":"Akkari, L. et al. Defining myeloid-derived suppressor cells. Nat. Rev. Immunol. 24, 850\u2013857 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/cdd.2014.89","volume":"22","author":"C Riether","year":"2015","unstructured":"Riether, C., Sch\u00fcrch, C. M. & Ochsenbein, A. F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 22, 187\u2013198 (2015).","journal-title":"Cell Death Differ."},{"key":"2998_CR54","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41590-019-0402-5","volume":"20","author":"T Chavakis","year":"2019","unstructured":"Chavakis, T., Mitroulis, I. & Hajishengallis, G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat. Immunol. 20, 802\u2013811 (2019).","journal-title":"Nat. Immunol."},{"key":"2998_CR55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target. Ther. 6, 362 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2017.01.004","volume":"38","author":"S Boettcher","year":"2017","unstructured":"Boettcher, S. & Manz, M. G. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol. 38, 345\u2013357 (2017).","journal-title":"Trends Immunol."},{"key":"2998_CR57","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s12276-024-01192-4","volume":"56","author":"DAG Barisas","year":"2024","unstructured":"Barisas, D. A. G. & Choi, K. Extramedullary hematopoiesis in cancer. Exp. Mol. Med. 56, 549\u2013558 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2998_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","volume":"32","author":"T Condamine","year":"2011","unstructured":"Condamine, T. & Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19\u201325 (2011).","journal-title":"Trends Immunol."},{"key":"2998_CR59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2998_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41588-023-01348-4","volume":"55","author":"T Narita","year":"2023","unstructured":"Narita, T. et al. Acetylation of histone H2B marks active enhancers and predicts CBP\/p300 target genes. Nat. Genet. 55, 679\u2013692 (2023).","journal-title":"Nat. Genet."},{"key":"2998_CR61","doi-asserted-by":"publisher","first-page":"e003549","DOI":"10.1136\/jitc-2021-003549","volume":"10","author":"F De Sanctis","year":"2022","unstructured":"De Sanctis, F. et al. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. J. Immunother. Cancer 10, e003549 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR62","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/ncb1507","volume":"8","author":"S Hiratsuka","year":"2006","unstructured":"Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8, 1369\u20131375 (2006).","journal-title":"Nat. Cell Biol."},{"key":"2998_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-23","volume":"11","author":"M Schuster","year":"2013","unstructured":"Schuster, M., Annemann, M., Plaza-Sirvent, C. & Schmitz, I. Atypical I\u03baB proteins \u2013 nuclear modulators of NF-\u03baB signaling. Cell Commun. Signal. 11, 23 (2013).","journal-title":"Cell Commun. Signal."},{"key":"2998_CR64","doi-asserted-by":"publisher","first-page":"1656165","DOI":"10.3389\/fimmu.2025.1656165","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang, J., Li, Y. & Xia, Y. C\/EBP\u03b2 as a master regulator of inflammasome signaling in neurodegenerative diseases: mechanisms and therapeutic implications. Front. Immunol. 16, 1656165 (2025).","journal-title":"Front. Immunol."},{"key":"2998_CR65","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2019.01804","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang, W., Xia, X., Mao, L. & Wang, S. The CCAAT\/enhancer-binding protein family: Its roles in MDSC expansion and function. Front. Immunol. 10, 1804 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572323","volume":"11","author":"E Safarzadeh","year":"2020","unstructured":"Safarzadeh, E. et al. MicroRNAs and lncRNAs\u2014a new layer of myeloid-derived suppressor cells regulation. Front. Immunol. 11, 572323 (2020).","journal-title":"Front. Immunol."},{"key":"2998_CR67","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/cac2.12546","volume":"44","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. Converting \u201ccold\u201d to \u201chot\u201d: epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer Commun. 44, 601\u2013636 (2024).","journal-title":"Cancer Commun."},{"key":"2998_CR68","doi-asserted-by":"crossref","unstructured":"Leija Montoya, G. et al. Long non-coding RNAs: regulators of the activity of myeloid-derived suppressor cells. Front. Immunol. 10, 1734 (2019).","DOI":"10.3389\/fimmu.2019.01734"},{"key":"2998_CR69","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.7150\/ijbs.44420","volume":"16","author":"L Zhou","year":"2020","unstructured":"Zhou, L., Zhu, Y., Sun, D. & Zhang, Q. Emerging roles of long non-coding RNAs in the tumor microenvironment. Int. J. Biol. Sci. 16, 2094\u20132103 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"2998_CR70","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3389\/fimmu.2019.01661","volume":"10","author":"Y Gao","year":"2019","unstructured":"Gao, Y. et al. Lnc-C\/EBP\u03b2 modulates differentiation of MDSCs through downregulating IL4i1 with C\/EBP\u03b2 LIP and WDR5. Front. Immunol. 10, 1661 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00011-022-01639-2","volume":"71","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. C\/EBP\u03b2 enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification. Inflamm. Res. 71, 1547\u20131557 (2022).","journal-title":"Inflamm. Res."},{"key":"2998_CR72","doi-asserted-by":"publisher","first-page":"619253","DOI":"10.3389\/fimmu.2020.619253","volume":"11","author":"N Fultang","year":"2021","unstructured":"Fultang, N., Li, X., Li, T. & Chen, Y. H. Myeloid-derived suppressor cell differentiation in cancer: transcriptional regulators and enhanceosome-mediated mechanisms. Front. Immunol. 11, 619253 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR73","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","volume":"27","author":"A Hashimoto","year":"2021","unstructured":"Hashimoto, A. et al. Upregulation of C\/EBP\u03b1 inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin. Cancer Res. 27, 5961\u20135978 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y., Yi, M., Niu, M., Mei, Q. & Wu, K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"2998_CR75","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s43018-020-0061-3","volume":"1","author":"T Li","year":"2020","unstructured":"Li, T. et al. c-rel is a myeloid checkpoint for cancer immunotherapy. Nat. Cancer 1, 507\u2013517 (2020).","journal-title":"Nat. Cancer"},{"key":"2998_CR76","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1182\/blood-2005-09-3691","volume":"108","author":"W-G Deng","year":"2006","unstructured":"Deng, W.-G., Tang, S.-T., Tseng, H.-P. & Wu, K. K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108, 518\u2013524 (2006).","journal-title":"Blood"},{"key":"2998_CR77","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1097\/01.ASN.0000024253.59665.F1","volume":"13","author":"Z Yu","year":"2002","unstructured":"Yu, Z., Zhang, W. & Kone, B. C. Histone deacetylases augment cytokine induction of the iNOS gene. J. Am. Soc. Nephrol. 13, 2009\u20132017 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2998_CR78","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1021\/jf9025713","volume":"57","author":"C-S Lai","year":"2009","unstructured":"Lai, C.-S. et al. Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-\u03baB, STAT3 and C\/EBP signaling pathways. J. Agric. Food Chem. 57, 10990\u201310998 (2009).","journal-title":"J. Agric. Food Chem."},{"key":"2998_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-02028-4","volume":"17","author":"M Mota","year":"2020","unstructured":"Mota, M. et al. Neuroprotective epi-drugs quench the inflammatory response and microglial\/macrophage activation in a mouse model of permanent brain ischemia. J. Neuroinflam. 17, 361 (2020).","journal-title":"J. Neuroinflam."},{"key":"2998_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"S Grivennikov","year":"2010","unstructured":"Grivennikov, S. & Karin, M. Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11\u201319 (2010).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2998_CR81","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ymthe.2025.11.031","volume":"34","author":"K Holm","year":"2026","unstructured":"Holm, K. et al. C\/EBP\u03b2 stabilizes oxidative stress in triple-negative breast cancer cells, driving taxane resistance and immune evasion. Mol. Ther. 34, 1503\u20131519 (2026).","journal-title":"Mol. Ther."},{"key":"2998_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02583-z","volume":"25","author":"Y Zhou","year":"2026","unstructured":"Zhou, Y. et al. Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression. Mol. Cancer 25, 81 (2026).","journal-title":"Mol. Cancer"},{"key":"2998_CR83","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/mco2.104","volume":"2","author":"T Zhang","year":"2021","unstructured":"Zhang, T., Ma, C., Zhang, Z., Zhang, H. & Hu, H. NF-\u03baB signaling in inflammation and cancer. MedComm 2, 618\u2013653 (2021).","journal-title":"MedComm"},{"key":"2998_CR84","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/hep.30676","volume":"70","author":"Y-M Li","year":"2019","unstructured":"Li, Y.-M. et al. Receptor-interacting protein kinase 3 deficiency recruits myeloid-derived suppressor cells to hepatocellular carcinoma through the chemokine (C-X-C motif) ligand 1\u2013chemokine (C-X-C motif) receptor 2 axis. Hepatology 70, 1564\u20131581 (2019).","journal-title":"Hepatology"},{"key":"2998_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13115","volume":"54","author":"M Xu","year":"2021","unstructured":"Xu, M., Wang, Y., Xia, R., Wei, Y. & Wei, X. Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting. Cell Prolif. 54, e13115 (2021).","journal-title":"Cell Prolif."},{"key":"2998_CR86","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/gutjnl-2022-327230","volume":"72","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Targeting tumour-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy. Gut 72, 1555\u20131567 (2023).","journal-title":"Gut"},{"key":"2998_CR87","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nature13862","volume":"515","author":"L Bonapace","year":"2014","unstructured":"Bonapace, L. et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130\u2013133 (2014).","journal-title":"Nature"},{"key":"2998_CR88","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra67 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2998_CR89","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/0008-5472.CAN-17-0348","volume":"78","author":"C Blattner","year":"2018","unstructured":"Blattner, C. et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res 78, 157\u2013167 (2018).","journal-title":"Cancer Res"},{"key":"2998_CR90","doi-asserted-by":"publisher","first-page":"1757513","DOI":"10.3389\/fimmu.2026.1757513","volume":"17","author":"W Zhang","year":"2026","unstructured":"Zhang, W. et al. Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. Front. Immunol. 17, 1757513 (2026).","journal-title":"Front. Immunol."},{"key":"2998_CR91","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P. & Kalinski, P. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71, 7463\u20137470 (2011).","journal-title":"Cancer Res"},{"key":"2998_CR92","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi, Y., Riese, D. J. & Shen, J. The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer. Front. Pharmacol. 11, 574667 (2020).","journal-title":"Front. Pharmacol."},{"key":"2998_CR93","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","volume":"29","author":"R Sun","year":"2021","unstructured":"Sun, R. et al. Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol. Ther. 29, 60\u201374 (2021).","journal-title":"Mol. Ther."},{"key":"2998_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Lactate and lactylation in cancer. Signal Transduct. Target. Ther. 10, 38 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR95","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z Li","year":"2021","unstructured":"Li, Z., Sun, C. & Qin, Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics 11, 8322\u20138336 (2021).","journal-title":"Theranostics"},{"key":"2998_CR96","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40164-025-00719-3","volume":"14","author":"X Ji","year":"2025","unstructured":"Ji, X. & Xia, L. Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming. Exp. Hematol. Oncol. 14, 128 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2998_CR97","doi-asserted-by":"publisher","first-page":"1113739","DOI":"10.3389\/fnut.2023.1113739","volume":"10","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Lactate in the tumor microenvironment: a rising star for targeted tumor therapy. Front. Nutr. 10, 1113739 (2023).","journal-title":"Front. Nutr."},{"key":"2998_CR98","doi-asserted-by":"publisher","first-page":"100740","DOI":"10.1016\/j.omto.2023.100740","volume":"31","author":"Z Li","year":"2023","unstructured":"Li, Z. & Cui, J. Targeting the lactic acid metabolic pathway for antitumor therapy. Mol. Ther. Oncolytics. 31, 100740 (2023).","journal-title":"Mol. Ther. Oncolytics."},{"key":"2998_CR99","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol. Res. 8, 1440\u20131451 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR100","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","volume":"26","author":"J He","year":"2025","unstructured":"He, J. et al. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. Nat. Immunol. 26, 391\u2013403 (2025).","journal-title":"Nat. Immunol."},{"key":"2998_CR101","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","volume":"67","author":"TM Nywening","year":"2018","unstructured":"Nywening, T. M. et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67, 1112\u20131123 (2018).","journal-title":"Gut"},{"key":"2998_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02597-7","volume":"25","author":"VK Somani","year":"2026","unstructured":"Somani, V. K. et al. Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic. Mol. Cancer 25, 65 (2026).","journal-title":"Mol. Cancer"},{"key":"2998_CR103","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3389\/fimmu.2020.01126","volume":"11","author":"C Wu","year":"2020","unstructured":"Wu, C., Hua, Q. & Zheng, L. Generation of myeloid cells in cancer: the spleen matters. Front. Immunol. 11, 1126 (2020).","journal-title":"Front. Immunol."},{"key":"2998_CR104","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/08820139.2017.1360339","volume":"46","author":"M Sevmis","year":"2017","unstructured":"Sevmis, M. et al. Splenectomy-induced leukocytosis promotes intratumoral accumulation of myeloid-derived suppressor cells, angiogenesis and metastasis. Immunol. Invest. 46, 663\u2013676 (2017).","journal-title":"Immunol. Invest."},{"key":"2998_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09728-3","volume":"10","author":"H-W Cheng","year":"2019","unstructured":"Cheng, H.-W. et al. Origin and differentiation trajectories of fibroblastic reticular cells in the splenic white pulp. Nat. Commun. 10, 1739 (2019).","journal-title":"Nat. Commun."},{"key":"2998_CR106","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41590-023-01690-z","volume":"25","author":"D Liu","year":"2024","unstructured":"Liu, D. et al. Dynamic encounters with red blood cells trigger splenic marginal zone B cell retention and function. Nat. Immunol. 25, 142\u2013154 (2024).","journal-title":"Nat. Immunol."},{"key":"2998_CR107","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nri1669","volume":"5","author":"RE Mebius","year":"2005","unstructured":"Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat. Rev. Immunol. 5, 606\u2013616 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR108","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/imm.12469","volume":"145","author":"BS Steiniger","year":"2015","unstructured":"Steiniger, B. S. Human spleen microanatomy: why mice do not suffice. Immunology 145, 334\u2013346 (2015).","journal-title":"Immunology"},{"key":"2998_CR109","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","volume":"31","author":"C Summers","year":"2010","unstructured":"Summers, C. et al. Neutrophil kinetics in health and disease. Trends Immunol. 31, 318\u2013324 (2010).","journal-title":"Trends Immunol."},{"key":"2998_CR110","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu, C. et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J. Clin. Invest. 128, 3425\u20133438 (2018).","journal-title":"J. Clin. Invest."},{"key":"2998_CR111","doi-asserted-by":"publisher","first-page":"e00027","DOI":"10.1002\/advs.202600027","volume":"13","author":"Y Liu","year":"2026","unstructured":"Liu, Y., Nie, X. & Gao, X. Tumor-induced splenic remodeling: mechanisms of systemic immunosuppression and emerging therapeutic opportunities. Adv. Sci. 13, e00027 (2026).","journal-title":"Adv. Sci."},{"key":"2998_CR112","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1073\/pnas.1113744109","volume":"109","author":"V Cortez-Retamozo","year":"2012","unstructured":"Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. 109, 2491\u20132496 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2998_CR113","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain, F. et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 3, 1236\u20131247 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR114","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/eji.201041069","volume":"41","author":"JM Haverkamp","year":"2011","unstructured":"Haverkamp, J. M., Crist, S. A., Elzey, B. D., Cimen, C. & Ratliff, T. L. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 41, 749\u2013759 (2011).","journal-title":"Eur. J. Immunol."},{"key":"2998_CR115","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806\u2013818 (2013).","journal-title":"Immunity"},{"key":"2998_CR116","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3389\/fimmu.2018.02499","volume":"9","author":"K Ohl","year":"2018","unstructured":"Ohl, K. & Tenbrock, K. Reactive oxygen species as regulators of MDSC-mediated immune suppression. Front. Immunol. 9, 2499 (2018).","journal-title":"Front. Immunol."},{"key":"2998_CR117","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641\u2013654 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR118","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"2998_CR119","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-\u03b21. J. Immunol. 182, 240\u2013249 (2009).","journal-title":"J. Immunol."},{"key":"2998_CR120","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41423-020-00556-w","volume":"18","author":"L Strauss","year":"2021","unstructured":"Strauss, L., Guarneri, V., Gennari, A. & Sica, A. Implications of metabolism-driven myeloid dysfunctions in cancer therapy. Cell. Mol. Immunol. 18, 829\u2013841 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR121","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41423-026-01411-0","volume":"23","author":"Y-W Du","year":"2026","unstructured":"Du, Y.-W. et al. Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment. Cell. Mol. Immunol. 23, 457\u2013470 (2026).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR122","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics 15, 2159\u20132184 (2025).","journal-title":"Theranostics"},{"key":"2998_CR123","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia, F. et al. Fatty acid transporter 2 reprograms neutrophils in cancer. Nature 569, 73\u201378 (2019).","journal-title":"Nature"},{"key":"2998_CR124","doi-asserted-by":"publisher","unstructured":"Lin, J. et al. Arachidonic acid metabolism in PMN-MDSCs suppresses antitumor capacity of T cells in KRAS-mutant cholangiocarcinoma. Cancer Discov. OF1\u2013OF21 (2026) https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1844.","DOI":"10.1158\/2159-8290.CD-25-1844"},{"key":"2998_CR125","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","volume":"20","author":"Y Mao","year":"2014","unstructured":"Mao, Y. et al. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20, 4096\u20134106 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/0008-5472.CAN-21-3054","volume":"82","author":"KC Hicks","year":"2022","unstructured":"Hicks, K. C., Tyurina, Y. Y., Kagan, V. E. & Gabrilovich, D. I. Myeloid cell\u2013derived oxidized lipids and regulation of the tumor microenvironment. Cancer Res 82, 187\u2013194 (2022).","journal-title":"Cancer Res"},{"key":"2998_CR127","first-page":"3930","volume":"118","author":"P Sonveaux","year":"2008","unstructured":"Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930\u20133942 (2008).","journal-title":"J. Clin. Invest."},{"key":"2998_CR128","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"2998_CR129","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"X-Y Gu","year":"2025","unstructured":"Gu, X.-Y. et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front. Immunol. 16, 1563303 (2025).","journal-title":"Front. Immunol."},{"key":"2998_CR130","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.21037\/jgo-24-368","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Lactic acid: A narrative review of a promoter of the liver cancer microenvironment. J. Gastrointest. Oncol. 15, 1282\u20131296 (2024).","journal-title":"J. Gastrointest. Oncol."},{"key":"2998_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03385-8","volume":"22","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Lactate accumulation from HIF-1\u03b1-mediated PMN-MDSC glycolysis restricts brain injury after acute hypoxia in neonates. J. Neuroinflam. 22, 59 (2025).","journal-title":"J. Neuroinflam."},{"key":"2998_CR132","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/med.21771","volume":"41","author":"L You","year":"2021","unstructured":"You, L. et al. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med. Res. Rev. 41, 1622\u20131643 (2021).","journal-title":"Med. Res. Rev."},{"key":"2998_CR133","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41388-026-03737-5","volume":"45","author":"X Wei","year":"2026","unstructured":"Wei, X. et al. LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer. Oncogene 45, 1544\u20131556 (2026).","journal-title":"Oncogene"},{"key":"2998_CR134","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","volume":"74","author":"G Liu","year":"2014","unstructured":"Liu, G. et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1\u03b1\u2013dependent glycolysis. Cancer Res. 74, 727\u2013737 (2014).","journal-title":"Cancer Res."},{"key":"2998_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.323","volume":"4","author":"R Ren","year":"2023","unstructured":"Ren, R. et al. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers. MedComm 4, e323 (2023).","journal-title":"MedComm"},{"key":"2998_CR136","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201803","volume":"218","author":"F Veglia","year":"2021","unstructured":"Veglia, F. et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J. Exp. Med. 218, e20201803 (2021).","journal-title":"J. Exp. Med."},{"key":"2998_CR137","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3736","volume":"9","author":"OS Sarkar","year":"2023","unstructured":"Sarkar, O. S. et al. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. Sci. Adv. 9, eadg3736 (2023).","journal-title":"Sci. Adv."},{"key":"2998_CR138","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","volume":"7","author":"R Trovato","year":"2019","unstructured":"Trovato, R. et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J. Immunother. Cancer 7, 255 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR139","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo, C. A. et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439\u20132453 (2010).","journal-title":"J. Exp. Med."},{"key":"2998_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K. & Smyth, M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell. Mol. Immunol. 17, 1\u201312 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR141","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2326-6066.CIR-13-0073","volume":"1","author":"Y Yin","year":"2013","unstructured":"Yin, Y., Huang, X., Lynn, K. D. & Thorpe, P. E. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol. Res. 1, 256\u2013268 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02249-2","volume":"24","author":"S-Y Park","year":"2025","unstructured":"Park, S.-Y. et al. Harnessing myeloid cells in cancer. Mol. Cancer 24, 69 (2025).","journal-title":"Mol. Cancer"},{"key":"2998_CR143","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","volume":"172","author":"MF Tavazoie","year":"2018","unstructured":"Tavazoie, M. F. et al. LXR\/ApoE activation restricts innate immune suppression in cancer. Cell 172, 825\u2013840.e18 (2018).","journal-title":"Cell"},{"key":"2998_CR144","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fimmu.2018.00608","volume":"9","author":"D Bayik","year":"2018","unstructured":"Bayik, D., Tross, D. & Klinman, D. M. Factors influencing the differentiation of human monocytic myeloid-derived suppressor cells into inflammatory macrophages. Front. Immunol. 9, 608 (2018).","journal-title":"Front. Immunol."},{"key":"2998_CR145","doi-asserted-by":"publisher","first-page":"1550893","DOI":"10.3389\/fimmu.2025.1550893","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang, X., Wang, Y., Yang, L., Zhang, Y. & Yang, L. TREM2+ macrophages: a key role in disease development. Front. Immunol. 16, 1550893 (2025).","journal-title":"Front. Immunol."},{"key":"2998_CR146","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.7150\/ijbs.91519","volume":"20","author":"C Fang","year":"2024","unstructured":"Fang, C. et al. TREM2 promotes macrophage polarization from M1 to M2 and suppresses osteoarthritis through the NF-\u03baB\/CXCL3 axis. Int. J. Biol. Sci. 20, 1992\u20132007 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"2998_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400524","volume":"11","author":"L Dong","year":"2024","unstructured":"Dong, L. et al. SPP1+ TAM regulates the metastatic colonization of CXCR4+ metastasis-associated tumor cells by remodeling the lymph node microenvironment. Adv. Sci. 11, 2400524 (2024).","journal-title":"Adv. Sci."},{"key":"2998_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1429","volume":"13","author":"X Huo","year":"2023","unstructured":"Huo, X. et al. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma. Clin. Transl. Med. 13, e1429 (2023).","journal-title":"Clin. Transl. Med."},{"key":"2998_CR149","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/2326-6066.CIR-18-0272","volume":"7","author":"H Zha","year":"2019","unstructured":"Zha, H. et al. Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages. Cancer Immunol. Res. 7, 193\u2013207 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR150","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J. Exp. Clin. Cancer Res. 40, 24 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2998_CR151","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-13-1686","volume":"74","author":"P Cheng","year":"2014","unstructured":"Cheng, P. et al. Effects of notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res. 74, 141\u2013152 (2014).","journal-title":"Cancer Res."},{"key":"2998_CR152","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp. Hematol. Oncol. 13, 39 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2998_CR153","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/med.70015","volume":"46","author":"J Zhang","year":"2026","unstructured":"Zhang, J., Wang, S., Liu, H., Luo, L. & You, J. Arginine competition in tumor microenvironment: a potential target for cancer therapy. Med. Res. Rev. 46, 382\u2013407 (2026).","journal-title":"Med. Res. Rev."},{"key":"2998_CR154","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-025-01038-9","volume":"47","author":"E Karadima","year":"2025","unstructured":"Karadima, E., Chavakis, T. & Alexaki, V. I. Arginine metabolism in myeloid cells in health and disease. Semin. Immunopathol. 47, 11 (2025).","journal-title":"Semin. Immunopathol."},{"key":"2998_CR155","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41577-024-01098-2","volume":"25","author":"S Can\u00e8","year":"2025","unstructured":"Can\u00e8, S., Geiger, R. & Bronte, V. The roles of arginases and arginine in immunity. Nat. Rev. Immunol. 25, 266\u2013284 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR156","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2006","unstructured":"Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568\u20131573 (2006).","journal-title":"Blood"},{"key":"2998_CR157","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","volume":"75","author":"M Fletcher","year":"2015","unstructured":"Fletcher, M. et al. l-arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 75, 275\u2013283 (2015).","journal-title":"Cancer Res."},{"key":"2998_CR158","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.CIR-15-0095","volume":"3","author":"N van Baren","year":"2015","unstructured":"van Baren, N. & Van den Eynde, B. J. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol. Res. 3, 978\u2013985 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR159","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u20131274 (2003).","journal-title":"Nat. Med."},{"key":"2998_CR160","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","volume":"15","author":"L Zhai","year":"2018","unstructured":"Zhai, L. et al. IDO1 in cancer: a gemini of immune checkpoints. Cell. Mol. Immunol. 15, 447\u2013457 (2018).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR161","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","volume":"13","author":"RB Holmgaard","year":"2015","unstructured":"Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 13, 412\u2013424 (2015).","journal-title":"Cell Rep."},{"key":"2998_CR162","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.celrep.2016.10.079","volume":"17","author":"L-AV de Velde","year":"2016","unstructured":"de Velde, L.-A. V. et al. Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep. 17, 2247\u20132258 (2016).","journal-title":"Cell Rep."},{"key":"2998_CR163","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cac2.12182","volume":"41","author":"Q Wu","year":"2021","unstructured":"Wu, Q., Yu, X., Li, J., Sun, S. & Tu, Y. Metabolic regulation in the immune response to cancer. Cancer Commun. 41, 661\u2013694 (2021).","journal-title":"Cancer Commun."},{"key":"2998_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a treg-macrophage suppressive axis induced by L-kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"2998_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912279","volume":"13","author":"J Lian","year":"2022","unstructured":"Lian, J. et al. The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. Front. Immunol. 13, 912279 (2022).","journal-title":"Front. Immunol."},{"key":"2998_CR166","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.immuni.2017.01.005","volume":"46","author":"G Mondanelli","year":"2017","unstructured":"Mondanelli, G. et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46, 233\u2013244 (2017).","journal-title":"Immunity"},{"key":"2998_CR167","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ni.2077","volume":"12","author":"MT Pallotta","year":"2011","unstructured":"Pallotta, M. T. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870\u2013878 (2011).","journal-title":"Nat. Immunol."},{"key":"2998_CR168","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.it.2020.09.007","volume":"41","author":"E Proietti","year":"2020","unstructured":"Proietti, E., Rossini, S., Grohmann, U. & Mondanelli, G. Polyamines and kynurenines at the intersection of immune modulation. Trends Immunol. 41, 1037\u20131050 (2020).","journal-title":"Trends Immunol."},{"key":"2998_CR169","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12979-021-00244-x","volume":"18","author":"IDCG da Silva","year":"2021","unstructured":"da Silva, I. D. C. G., Marchioni, D. M. L., Carioca, A. A. F., Bueno, V. & Colleoni, G. W. B. May critical molecular cross-talk between indoleamine 2,3-dioxygenase (IDO) and arginase during human aging be targets for immunosenescence control? Immun. Ageing 18, 33 (2021).","journal-title":"Immun. Ageing"},{"key":"2998_CR170","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-023-02830-x","volume":"42","author":"R Ruiu","year":"2023","unstructured":"Ruiu, R. et al. Cystine\/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models. J. Exp. Clin. Cancer Res. 42, 254 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2998_CR171","doi-asserted-by":"publisher","first-page":"1226443","DOI":"10.3389\/fimmu.2023.1226443","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang, J., Zhao, Y., Zhao, K., Yin, K. & Wang, S. Function of reactive oxygen species in myeloid-derived suppressor cells. Front. Immunol. 14, 1226443 (2023).","journal-title":"Front. Immunol."},{"key":"2998_CR172","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-015-0194-3","volume":"22","author":"AV Belikov","year":"2015","unstructured":"Belikov, A. V., Schraven, B. & Simeoni, L. T cells and reactive oxygen species. J. Biomed. Sci. 22, 85 (2015).","journal-title":"J. Biomed. Sci."},{"key":"2998_CR173","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-042617-053335","volume":"36","author":"BB Au-Yeung","year":"2018","unstructured":"Au-Yeung, B. B., Shah, N. H., Shen, L. & Weiss, A. ZAP-70 in signaling, biology, and disease. Annu. Rev. Immunol. 36, 127\u2013156 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"2998_CR174","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cac2.12156","volume":"41","author":"C Cui","year":"2021","unstructured":"Cui, C., Lan, P. & Fu, L. The role of myeloid-derived suppressor cells in gastrointestinal cancer. Cancer Commun. 41, 442\u2013471 (2021).","journal-title":"Cancer Commun."},{"key":"2998_CR175","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1158\/1078-0432.CCR-07-0182","volume":"13","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13, 5243\u20135248 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR176","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1034\/j.1600-065X.2003.00047.x","volume":"193","author":"A Krueger","year":"2003","unstructured":"Krueger, A., Fas, S. C., Baumann, S. & Krammer, P. H. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol. Rev. 193, 58\u201369 (2003).","journal-title":"Immunol. Rev."},{"key":"2998_CR177","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1074-7613(00)80566-X","volume":"8","author":"Y Refaeli","year":"1998","unstructured":"Refaeli, Y., Parijs, L. V., London, C. A., Tschopp, J. & Abbas, A. K. Biochemical mechanisms of IL-2\u2013regulated fas-mediated T cell apoptosis. Immunity 8, 615\u2013623 (1998).","journal-title":"Immunity"},{"key":"2998_CR178","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.4049\/jimmunol.161.12.6526","volume":"161","author":"MS Williams","year":"1998","unstructured":"Williams, M. S., Noguchi, S., Henkart, P. A. & Osawa, Y. Nitric oxide synthase plays a signaling role in TCR-triggered apoptotic death. J. Immunol. 161, 6526\u20136531 (1998).","journal-title":"J. Immunol."},{"key":"2998_CR179","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc2202","volume":"7","author":"O Leavy","year":"2007","unstructured":"Leavy, O. New mechanism of tolerance induction in cancer. Nat. Rev. Cancer 7, 572 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"2998_CR180","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1084\/jem.20101956","volume":"208","author":"B Molon","year":"2011","unstructured":"Molon, B. et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208, 1949\u20131962 (2011).","journal-title":"J. Exp. Med."},{"key":"2998_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf, P. et al. Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol. Cancer 22, 207 (2023).","journal-title":"Mol. Cancer"},{"key":"2998_CR182","doi-asserted-by":"publisher","first-page":"e1247135","DOI":"10.1080\/2162402X.2016.1247135","volume":"5","author":"C Lu","year":"2016","unstructured":"Lu, C., Redd, P. S., Lee, J. R., Savage, N. & Liu, K. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. OncoImmunology 5, e1247135 (2016).","journal-title":"OncoImmunology"},{"key":"2998_CR183","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: Teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2998_CR184","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","volume":"24","author":"A Christofides","year":"2023","unstructured":"Christofides, A. et al. SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses. Nat. Immunol. 24, 55\u201368 (2023).","journal-title":"Nat. Immunol."},{"key":"2998_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00784-1","volume":"8","author":"J Zhu","year":"2017","unstructured":"Zhu, J. et al. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat. Commun. 8, 1404 (2017).","journal-title":"Nat. Commun."},{"key":"2998_CR186","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/cmi.2014.21","volume":"12","author":"F Yang","year":"2015","unstructured":"Yang, F. et al. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via fas signaling. Cell. Mol. Immunol. 12, 66\u201376 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR187","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1182\/blood-2010-11-321752","volume":"117","author":"P Sinha","year":"2011","unstructured":"Sinha, P. et al. Myeloid-derived suppressor cells express the death receptor fas and apoptose in response to T cell\u2013expressed FasL. Blood 117, 5381\u20135390 (2011).","journal-title":"Blood"},{"key":"2998_CR188","doi-asserted-by":"publisher","first-page":"a016873","DOI":"10.1101\/cshperspect.a016873","volume":"5","author":"T Ten Broeke","year":"2013","unstructured":"Ten Broeke, T., Wubbolts, R. & Stoorvogel, W. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harb. Perspect. Biol. 5, a016873 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2998_CR189","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105\u2013115 (2013).","journal-title":"Immunology"},{"key":"2998_CR190","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1004983","volume":"5","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y., Wu, T., Shao, S., Shi, B. & Zhao, Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. OncoImmunology 5, e1004983 (2016).","journal-title":"OncoImmunology"},{"key":"2998_CR191","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3389\/fimmu.2019.01068","volume":"10","author":"A Ivetic","year":"2019","unstructured":"Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: a major regulator of leukocyte adhesion, migration and signaling. Front. Immunol. 10, 1068 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR192","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.17375","volume":"5","author":"AW Ku","year":"2016","unstructured":"Ku, A. W. et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. eLife 5, e17375 (2016).","journal-title":"eLife"},{"key":"2998_CR193","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2019.06.004","volume":"142","author":"H Zhang","year":"2019","unstructured":"Zhang, H., Wang, L. & Chu, Y. Reactive oxygen species: the signal regulator of B cell. Free Radic. Biol. Med. 142, 16\u201322 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"2998_CR194","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/s41388-018-0668-3","volume":"38","author":"S Das","year":"2019","unstructured":"Das, S. & Bar-Sagi, D. BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene 38, 3316\u20133324 (2019).","journal-title":"Oncogene"},{"key":"2998_CR195","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-016-0145-x","volume":"4","author":"M Schwartz","year":"2016","unstructured":"Schwartz, M., Zhang, Y. & Rosenblatt, J. D. B cell regulation of the anti-tumor response and role in carcinogenesis. J. Immunother. Cancer 4, 40 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03745-1","volume":"12","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1\u2212PD-L1+ bregs through PD-L1\/PI3K\/AKT\/NF-\u03baB axis in breast cancer. Cell Death Dis. 12, 465 (2021).","journal-title":"Cell Death Dis."},{"key":"2998_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0152-y","volume":"9","author":"B Peng","year":"2018","unstructured":"Peng, B., Ming, Y. & Yang, C. Regulatory B cells: The cutting edge of immune tolerance in kidney transplantation. Cell Death Dis. 9, 109 (2018).","journal-title":"Cell Death Dis."},{"key":"2998_CR198","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B Hoechst","year":"2009","unstructured":"Hoechst, B. et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799\u2013807 (2009).","journal-title":"Hepatology"},{"key":"2998_CR199","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","volume":"24","author":"A Stiff","year":"2018","unstructured":"Stiff, A. et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing fc receptor\u2013mediated natural killer cell function. Clin. Cancer Res. 24, 1891\u20131904 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan, S. et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol. Cancer 18, 29 (2019).","journal-title":"Mol. Cancer"},{"key":"2998_CR201","doi-asserted-by":"publisher","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes, M. B., Domaica, C. I. & Zwirner, N. W. Leveraging NKG2D ligands in immuno-oncology. Front. Immunol. 12, 713158 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR202","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel, S. et al. TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016).","journal-title":"Sci. Signal."},{"key":"2998_CR203","doi-asserted-by":"publisher","first-page":"734551","DOI":"10.3389\/fimmu.2021.734551","volume":"12","author":"EHC Lee","year":"2021","unstructured":"Lee, E. H. C., Wong, D. C. P. & Ding, J. L. NK cells in a tug-of-war with cancer: The roles of transcription factors and cytoskeleton. Front. Immunol. 12, 734551 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR204","doi-asserted-by":"publisher","first-page":"633685","DOI":"10.3389\/fimmu.2021.633685","volume":"12","author":"LS Carnevalli","year":"2021","unstructured":"Carnevalli, L. S., Ghadially, H. & Barry, S. T. Therapeutic approaches targeting the natural killer-myeloid cell axis in the tumor microenvironment. Front. Immunol. 12, 633685 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02643-4","volume":"25","author":"AR Redavid","year":"2026","unstructured":"Redavid, A. R., Bigliardi, M., Ciarrocchi, A. & Reggiani, F. Transcriptional networks weaving natural killer anti-tumor immune response. Mol. Cancer 25, 113 (2026).","journal-title":"Mol. Cancer"},{"key":"2998_CR206","doi-asserted-by":"publisher","first-page":"1671806","DOI":"10.3389\/fimmu.2026.1671806","volume":"17","author":"X Yang","year":"2026","unstructured":"Yang, X., Sun, M., Tang, X., Zhang, X. & Shen, W. T-bet: Biological functions, molecular mechanisms, and therapeutic applications: a systematic review. Front. Immunol. 17, 1671806 (2026).","journal-title":"Front. Immunol."},{"key":"2998_CR207","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2016.00128","volume":"7","author":"NA Cacalano","year":"2016","unstructured":"Cacalano, N. A. Regulation of natural killer cell function by STAT3. Front. Immunol. 7, 128 (2016).","journal-title":"Front. Immunol."},{"key":"2998_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front. Immunol. 12, 619195 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR209","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","volume":"27","author":"F Yang","year":"2024","unstructured":"Yang, F., Lee, G. & Fan, Y. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism. Angiogenesis 27, 333\u2013349 (2024).","journal-title":"Angiogenesis"},{"key":"2998_CR210","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618\u2013631 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2998_CR211","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1182\/blood-2005-04-1388","volume":"106","author":"A Salameh","year":"2005","unstructured":"Salameh, A., Galvagni, F., Bardelli, M., Bussolino, F. & Oliviero, S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106, 3423\u20133431 (2005).","journal-title":"Blood"},{"key":"2998_CR212","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","volume":"48","author":"FH Shah","year":"2025","unstructured":"Shah, F. H. et al. Targeting vascular endothelial growth receptor-2 (VEGFR-2): Structural biology, functional insights, and therapeutic resistance. Arch. Pharm. Res. 48, 404\u2013425 (2025).","journal-title":"Arch. Pharm. Res."},{"key":"2998_CR213","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","volume":"36","author":"LB Rivera","year":"2015","unstructured":"Rivera, L. B. & Bergers, G. Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 36, 240\u2013249 (2015).","journal-title":"Trends Immunol."},{"key":"2998_CR214","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1152\/physrev.00012.2017","volume":"98","author":"L Negri","year":"2018","unstructured":"Negri, L. & Ferrara, N. The prokineticins: Neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol. Rev. 98, 1055\u20131082 (2018).","journal-title":"Physiol. Rev."},{"key":"2998_CR215","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"H-R Park","year":"2023","unstructured":"Park, H.-R. et al. Angiopoietin-2\u2013dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 83, 1968\u20131983 (2023).","journal-title":"Cancer Res."},{"key":"2998_CR216","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.3390\/ijms20122970","volume":"20","author":"L Albonici","year":"2019","unstructured":"Albonici, L., Giganti, M. G., Modesti, A., Manzari, V. & Bei, R. Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int. J. Mol. Sci. 20, 2970 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2998_CR217","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease and therapeutics. Signal Transduct. Target. Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR218","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06119-x","volume":"14","author":"J Fang","year":"2023","unstructured":"Fang, J. et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 14, 586 (2023).","journal-title":"Cell Death Dis."},{"key":"2998_CR219","doi-asserted-by":"publisher","first-page":"108114","DOI":"10.1016\/j.pharmthera.2022.108114","volume":"235","author":"S Joshi","year":"2022","unstructured":"Joshi, S. & Sharabi, A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol. Ther. 235, 108114 (2022).","journal-title":"Pharmacol. Ther."},{"key":"2998_CR220","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1172\/JCI35213","volume":"118","author":"M Kujawski","year":"2008","unstructured":"Kujawski, M. et al. Stat3 mediates myeloid cell\u2013dependent tumor angiogenesis in mice. J. Clin. Invest. 118, 3367\u20133377 (2008).","journal-title":"J. Clin. Invest."},{"key":"2998_CR221","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11883-015-0509-6","volume":"17","author":"X Yang","year":"2015","unstructured":"Yang, X. et al. Fibroblast growth factor signaling in the vasculature. Curr. Atheroscler. Rep. 17, 509 (2015).","journal-title":"Curr. Atheroscler. Rep."},{"key":"2998_CR222","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00779-x","volume":"13","author":"X Liu","year":"2025","unstructured":"Liu, X. et al. Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies. Biomark. Res. 13, 62 (2025).","journal-title":"Biomark. Res."},{"key":"2998_CR223","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"R Ruan","year":"2023","unstructured":"Ruan, R. et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment. Mol. Cancer 22, 60 (2023).","journal-title":"Mol. Cancer"},{"key":"2998_CR224","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel, S., Sanctis, F. D., Mandruzzato, S. & Bronte, V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125, 3365\u20133376 (2015).","journal-title":"J. Clin. Invest."},{"key":"2998_CR225","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10555-025-10278-y","volume":"44","author":"S Kusmartsev","year":"2025","unstructured":"Kusmartsev, S. Metastasis-promoting functions of myeloid cells. Cancer Metastasis Rev. 44, 61 (2025).","journal-title":"Cancer Metastasis Rev."},{"key":"2998_CR226","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/cells8121647","volume":"8","author":"E-K Vetsika","year":"2019","unstructured":"Vetsika, E.-K., Koukos, A. & Kotsakis, A. Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer. Cells 8, 1647 (2019).","journal-title":"Cells"},{"key":"2998_CR227","doi-asserted-by":"publisher","first-page":"19485","DOI":"10.1073\/pnas.0909228106","volume":"106","author":"SLC Lee","year":"2009","unstructured":"Lee, S. L. C. et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. 106, 19485\u201319490 (2009).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2998_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189200","volume":"1879","author":"X Li","year":"2024","unstructured":"Li, X. et al. The role of ferroptosis resistance in lymph-associated tumour metastasis. Biochim. Biophys. Acta Rev. Cancer 1879, 189200 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2998_CR229","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-023-01576-4","volume":"8","author":"H Ji","year":"2023","unstructured":"Ji, H. et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct. Target. Ther. 8, 367 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR230","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fimmu.2019.00518","volume":"10","author":"RH Farnsworth","year":"2019","unstructured":"Farnsworth, R. H., Karnezis, T., Maciburko, S. J., Mueller, S. N. & Stacker, S. A. The interplay between lymphatic vessels and chemokines. Front. Immunol. 10, 518 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR231","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev-physiol-020518-114721","volume":"81","author":"M Mazzone","year":"2019","unstructured":"Mazzone, M. & Bergers, G. Regulation of blood and lymphatic vessels by immune cells in tumors and metastasis. Annu. Rev. Physiol. 81, 535\u2013560 (2019).","journal-title":"Annu. Rev. Physiol."},{"key":"2998_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111989","volume":"28","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. TAF7 directly targets SAA1 to enhance triple-negative breast cancer metastasis via phosphorylating E-cadherin and N-cadherin. iScience 28, 111989 (2025).","journal-title":"iScience"},{"key":"2998_CR233","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/cancers11081120","volume":"11","author":"J-Y Chen","year":"2019","unstructured":"Chen, J.-Y. et al. Cancer-derived VEGF-C increases chemokine production in lymphatic endothelial cells to promote CXCR2-dependent cancer invasion and MDSC recruitment. Cancers 11, 1120 (2019).","journal-title":"Cancers"},{"key":"2998_CR234","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.celrep.2019.07.072","volume":"28","author":"Y Yang","year":"2019","unstructured":"Yang, Y., Cha, B., Motawe, Z. Y., Srinivasan, R. S. & Scallan, J. P. VE-cadherin is required for lymphatic valve formation and maintenance. Cell Rep. 28, 2397\u20132412.e4 (2019).","journal-title":"Cell Rep."},{"key":"2998_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2023.5480","volume":"62","author":"A Kazakova","year":"2023","unstructured":"Kazakova, A., Sudarskikh, T., Kovalev, O., Kzhyshkowska, J. & Larionova, I. Interaction of tumor\u2011associated macrophages with stromal and immune components in solid tumors: research progress (review). Int. J. Oncol. 62, 1\u201321 (2023).","journal-title":"Int. J. Oncol."},{"key":"2998_CR236","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4, H., Llort Asens, M., Guenther, C. & Fagerholm, S. C. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10, 1078 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR237","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1158\/0008-5472.CAN-15-2528","volume":"76","author":"D Peng","year":"2016","unstructured":"Peng, D. et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6\/STAT3 and NO\/NOTCH cross-talk signaling. Cancer Res. 76, 3156\u20133165 (2016).","journal-title":"Cancer Res."},{"key":"2998_CR238","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","volume":"21","author":"D Bayik","year":"2021","unstructured":"Bayik, D. & Lathia, J. D. Cancer stem cell\u2013immune cell crosstalk in tumour progression. Nat. Rev. Cancer 21, 526\u2013536 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2998_CR239","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"MR de la Vega","year":"2018","unstructured":"de la Vega, M. R., Chapman, E. & Zhang, D. D. NRF2 and the hallmarks of cancer. Cancer Cell 34, 21\u201343 (2018).","journal-title":"Cancer Cell"},{"key":"2998_CR240","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/j.ymthe.2024.08.019","volume":"32","author":"Y Jo","year":"2024","unstructured":"Jo, Y. et al. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+ T and CAR-T cells. Mol. Ther. 32, 3879\u20133894 (2024).","journal-title":"Mol. Ther."},{"key":"2998_CR241","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.659","volume":"5","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Epithelial\u2013mesenchymal plasticity in cancer: signaling pathways and therapeutic targets. MedComm 5, e659 (2024).","journal-title":"MedComm"},{"key":"2998_CR242","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"2998_CR243","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1007\/s00018-021-03966-9","volume":"78","author":"Z Ling","year":"2021","unstructured":"Ling, Z., Yang, C., Tan, J., Dou, C. & Chen, Y. Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases. Cell. Mol. Life Sci. 78, 7161\u20137183 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"2998_CR244","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3390\/ijms20112767","volume":"20","author":"Y Hao","year":"2019","unstructured":"Hao, Y., Baker, D. & ten Dijke, P. TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis. Int. J. Mol. Sci. 20, 2767 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2998_CR245","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/0008-5472.CAN-19-2013","volume":"80","author":"B Jing","year":"2020","unstructured":"Jing, B. et al. IL6\/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung. Cancer Res. 80, 784\u2013797 (2020).","journal-title":"Cancer Res."},{"key":"2998_CR246","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0988-0","volume":"18","author":"Y-S Weng","year":"2019","unstructured":"Weng, Y.-S. et al. MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol. Cancer 18, 42 (2019).","journal-title":"Mol. Cancer"},{"key":"2998_CR247","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10555-023-10141-y","volume":"43","author":"D Singh","year":"2024","unstructured":"Singh, D. & Siddique, H. R. Epithelial-to-mesenchymal transition in cancer progression: Unraveling the immunosuppressive module driving therapy resistance. Cancer Metastasis Rev. 43, 155\u2013173 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2998_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"M Taki","year":"2018","unstructured":"Taki, M. et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat. Commun. 9, 1685 (2018).","journal-title":"Nat. Commun."},{"key":"2998_CR249","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1172\/JCI64115","volume":"122","author":"X Zhao","year":"2012","unstructured":"Zhao, X. et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122, 4094\u20134104 (2012).","journal-title":"J. Clin. Invest."},{"key":"2998_CR250","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00564-3","volume":"18","author":"S Naserian","year":"2020","unstructured":"Naserian, S. et al. The TNF\/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect. Cell Commun. Signal. 18, 94 (2020).","journal-title":"Cell Commun. Signal."},{"key":"2998_CR251","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0048-x","volume":"8","author":"Z Shen","year":"2017","unstructured":"Shen, Z. et al. MicroRNA-105 is involved in TNF-\u03b1-related tumor microenvironment enhanced colorectal cancer progression. Cell Death Dis. 8, 3213 (2017).","journal-title":"Cell Death Dis."},{"key":"2998_CR252","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/biomedicines13081945","volume":"13","author":"M Rosado-Sanz","year":"2025","unstructured":"Rosado-Sanz, M. et al. Cytokine networks in triple-negative breast cancer: mechanisms, therapeutic targets, and emerging strategies. Biomedicines 13, 1945 (2025).","journal-title":"Biomedicines"},{"key":"2998_CR253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu, D., Baldasici, O., Balacescu, O. & Berindan-Neagoe, I. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell. Oncol. 43, 1\u201318 (2020).","journal-title":"Cell. Oncol."},{"key":"2998_CR254","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"2998_CR255","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","volume":"14","author":"M Zhang","year":"2025","unstructured":"Zhang, M. & Zhang, B. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer. Exp. Hematol. Oncol. 14, 54 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2998_CR256","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Ding, Y., Guo, N. & Wang, S. MDSCs: key criminals of tumor pre-metastatic niche formation. Front. Immunol. 10, 172 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR257","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"2998_CR258","doi-asserted-by":"publisher","first-page":"036108","DOI":"10.1063\/5.0156628","volume":"7","author":"B Hu","year":"2023","unstructured":"Hu, B., Xin, Y., Hu, G., Li, K. & Tan, Y. Fluid shear stress enhances natural killer cell\u2019s cytotoxicity toward circulating tumor cells through NKG2D-mediated mechanosensing. APL Bioeng. 7, 036108 (2023).","journal-title":"APL Bioeng."},{"key":"2998_CR259","doi-asserted-by":"publisher","first-page":"975261","DOI":"10.3389\/fonc.2022.975261","volume":"12","author":"G Ya","year":"2022","unstructured":"Ya, G., Ren, W., Qin, R., He, J. & Zhao, S. Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche. Front. Oncol. 12, 975261 (2022).","journal-title":"Front. Oncol."},{"key":"2998_CR260","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000437","volume":"3","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Circulating tumour cell clusters: Isolation, biological significance and therapeutic implications. BMJ Oncol. 3, e000437 (2024).","journal-title":"BMJ Oncol."},{"key":"2998_CR261","doi-asserted-by":"publisher","first-page":"944487","DOI":"10.3389\/fonc.2022.944487","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen, Q. et al. A narrative review of circulating tumor cells clusters: a key morphology of cancer cells in circulation promote hematogenous metastasis. Front. Oncol. 12, 944487 (2022).","journal-title":"Front. Oncol."},{"key":"2998_CR262","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct. Target. Ther. 9, 236 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2998_CR263","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber, R. et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front. Immunol. 9, 1310 (2018).","journal-title":"Front. Immunol."},{"key":"2998_CR264","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin\u2013cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49\u201359 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR265","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s10238-022-00946-6","volume":"23","author":"G Bronte","year":"2022","unstructured":"Bronte, G., Calabr\u00f2, L., Olivieri, F., Procopio, A. D. & Crin\u00f2, L. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis. Clin. Exp. Med. 23, 1551\u20131561 (2022).","journal-title":"Clin. Exp. Med."},{"key":"2998_CR266","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","volume":"60","author":"RF Gabitass","year":"2011","unstructured":"Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A. & Middleton, G. W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the TH2 cytokine interleukin-13. Cancer Immunol. Immunother. 60, 1419\u20131430 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR267","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","volume":"1319","author":"S Solito","year":"2014","unstructured":"Solito, S. et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 1319, 47\u201365 (2014).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2998_CR268","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1494113","volume":"7","author":"P-F Wang","year":"2018","unstructured":"Wang, P.-F. et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. OncoImmunology 7, e1494113 (2018).","journal-title":"OncoImmunology"},{"key":"2998_CR269","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1641383","volume":"16","author":"Y Jin","year":"2025","unstructured":"Jin, Y. et al. Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma. Front. Immunol. 16, 1641383 (2025).","journal-title":"Front. Immunol."},{"key":"2998_CR270","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2998_CR271","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei, Q., Wang, D., Sun, K., Wang, L. & Zhang, Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front. Cell Dev. Biol. 8, 672 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2998_CR272","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2020.10.036","volume":"160","author":"W Kim","year":"2021","unstructured":"Kim, W. et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology 160, 781\u2013796 (2021).","journal-title":"Gastroenterology"},{"key":"2998_CR273","doi-asserted-by":"publisher","first-page":"1403771","DOI":"10.3389\/fimmu.2024.1403771","volume":"15","author":"M M\u00f6ller","year":"2024","unstructured":"M\u00f6ller, M. et al. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis. Front. Immunol. 15, 1403771 (2024).","journal-title":"Front. Immunol."},{"key":"2998_CR274","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1065767","volume":"14","author":"V Petrova","year":"2023","unstructured":"Petrova, V. et al. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients. Front. Immunol. 14, 1065767 (2023).","journal-title":"Front. Immunol."},{"key":"2998_CR275","doi-asserted-by":"publisher","first-page":"e006802","DOI":"10.1136\/jitc-2023-006802","volume":"11","author":"A Gai\u00dfler","year":"2023","unstructured":"Gai\u00dfler, A. et al. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J. Immunother. Cancer 11, e006802 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR276","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00333-5","volume":"9","author":"Z Hao","year":"2021","unstructured":"Hao, Z. et al. Landscape of myeloid-derived suppressor cell in tumor immunotherapy. Biomark. Res. 9, 77 (2021).","journal-title":"Biomark. Res."},{"key":"2998_CR277","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","volume":"70","author":"JS Ko","year":"2010","unstructured":"Ko, J. S. et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70, 3526\u20133536 (2010).","journal-title":"Cancer Res"},{"key":"2998_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595533","volume":"16","author":"M Chen","year":"2025","unstructured":"Chen, M. et al. Recent advances in tumor immunotherapy based on NK cells. Front. Immunol. 16, 1595533 (2025).","journal-title":"Front. Immunol."},{"key":"2998_CR279","doi-asserted-by":"publisher","first-page":"1157537","DOI":"10.3389\/fimmu.2023.1157537","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y., Du, J. & Shen, X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front. Immunol. 14, 1157537 (2023).","journal-title":"Front. Immunol."},{"key":"2998_CR280","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski, R., Markowitz, J. & Carson, W. E. Myeloid derived suppressor cells \u2013 a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 1, 10 (2013).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR281","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"J-I Youn","year":"2008","unstructured":"Youn, J.-I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791\u20135802 (2008).","journal-title":"J. Immunol."},{"key":"2998_CR282","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13287-020-01837-x","volume":"11","author":"J Qi","year":"2020","unstructured":"Qi, J. et al. Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2\/PGE2 in experimental sialadenitis. Stem Cell Res. Ther. 11, 325 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"2998_CR283","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2016.71.3743","volume":"35","author":"MJ Edelman","year":"2017","unstructured":"Edelman, M. J. et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non\u2013small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (alliance). J. Clin. Oncol. 35, 2184\u20132192 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2998_CR284","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","volume":"21","author":"NK Altorki","year":"2003","unstructured":"Altorki, N. K. et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non\u2013small-cell lung cancer. J. Clin. Oncol. 21, 2645\u20132650 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2998_CR285","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-08-0629","volume":"15","author":"R Mutter","year":"2009","unstructured":"Mutter, R. et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA\/B non\u2013small cell lung cancer. Clin. Cancer Res. 15, 2158\u20132165 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR286","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108\u2013119 (2018).","journal-title":"Nat. Immunol."},{"key":"2998_CR287","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrm763","volume":"3","author":"CE Brinckerhoff","year":"2002","unstructured":"Brinckerhoff, C. E. & Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3, 207\u2013214 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2998_CR288","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1126\/science.1067100","volume":"295","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer\u2014trials and tribulations. Science 295, 2387\u20132392 (2002).","journal-title":"Science"},{"key":"2998_CR289","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003495-200059050-00002","volume":"59","author":"EI Heath","year":"2000","unstructured":"Heath, E. I. & Grochow, L. B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59, 1043\u20131055 (2000).","journal-title":"Drugs"},{"key":"2998_CR290","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.trecan.2020.02.020","volume":"6","author":"EC Madden","year":"2020","unstructured":"Madden, E. C., Gorman, A. M., Logue, S. E. & Samali, A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer 6, 489\u2013505 (2020).","journal-title":"Trends Cancer"},{"key":"2998_CR291","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u2013842.e13 (2016).","journal-title":"Cell"},{"key":"2998_CR292","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","volume":"6","author":"GP Hartley","year":"2018","unstructured":"Hartley, G. P., Chow, L., Ammons, D. T., Wheat, W. H. & Dow, S. W. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol. Res. 6, 1260\u20131273 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2998_CR293","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16\u201325 (2019).","journal-title":"Br. J. Cancer"},{"key":"2998_CR294","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion, A. et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin. Cancer Res. 23, 5187\u20135201 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR295","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148\u20132157 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR296","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","volume":"69","author":"H Xin","year":"2009","unstructured":"Xin, H. et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506\u20132513 (2009).","journal-title":"Cancer Res."},{"key":"2998_CR297","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1600-065X.2008.00602.x","volume":"222","author":"I Marigo","year":"2008","unstructured":"Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162\u2013179 (2008).","journal-title":"Immunol. Rev."},{"key":"2998_CR298","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1172\/JCI68189","volume":"123","author":"JD Waight","year":"2013","unstructured":"Waight, J. D. et al. Myeloid-derived suppressor cell development is regulated by a STAT\/IRF-8 axis. J. Clin. Invest. 123, 4464\u20134478 (2013).","journal-title":"J. Clin. Invest."},{"key":"2998_CR299","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova, Y. et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67, 11021\u201311028 (2007).","journal-title":"Cancer Res."},{"key":"2998_CR300","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728\u2013732 (2017).","journal-title":"Nature"},{"key":"2998_CR301","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm1325","volume":"11","author":"M Kortylewski","year":"2005","unstructured":"Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314\u20131321 (2005).","journal-title":"Nat. Med."},{"key":"2998_CR302","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225\u20131235 (2008).","journal-title":"Nat. Immunol."},{"key":"2998_CR303","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1016\/j.cell.2022.09.027","volume":"185","author":"SK Varanasi","year":"2022","unstructured":"Varanasi, S. K., Kaech, S. M. & Bui, J. D. SnapShot: cancer immunoediting. Cell 185, 4038\u20134038.e1 (2022).","journal-title":"Cell"},{"key":"2998_CR304","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"2998_CR305","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329\u2013360 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"2998_CR306","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & Van Hall, T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44\u201351 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"2998_CR307","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-012-1321-6","volume":"61","author":"M Bernal","year":"2012","unstructured":"Bernal, M., Ruiz-Cabello, F., Concha, A., Paschen, A. & Garrido, F. Implication of the \u03b22-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol. Immunother. 61, 1359\u20131371 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR308","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0167-5699(00)01692-3","volume":"21","author":"B Seliger","year":"2000","unstructured":"Seliger, B., Maeurer, M. J. & Ferrone, S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455\u2013464 (2000).","journal-title":"Immunol. Today"},{"key":"2998_CR309","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e11 (2017).","journal-title":"Cell"},{"key":"2998_CR310","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"2998_CR311","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"2998_CR312","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2998_CR313","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2998_CR314","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","volume":"2","author":"LA Garraway","year":"2012","unstructured":"Garraway, L. A. & J\u00e4nne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214\u2013226 (2012).","journal-title":"Cancer Discov."},{"key":"2998_CR315","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1073\/pnas.1323934111","volume":"111","author":"B Zhao","year":"2014","unstructured":"Zhao, B., Hemann, M. T. & Lauffenburger, D. A. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc. Natl. Acad. Sci. 111, 10773\u201310778 (2014).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2998_CR316","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2998_CR317","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2998_CR318","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","volume":"4","author":"R Salgia","year":"2018","unstructured":"Salgia, R. & Kulkarni, P. The genetic\/non-genetic duality of drug \u2018resistance\u2019 in cancer. Trends Cancer 4, 110\u2013118 (2018).","journal-title":"Trends Cancer"},{"key":"2998_CR319","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u2013269 (2016).","journal-title":"Nat. Med."},{"key":"2998_CR320","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. M. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"2998_CR321","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","volume":"79","author":"S Huang","year":"2019","unstructured":"Huang, S. et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 79, 2009\u20132020 (2019).","journal-title":"Cancer Res."},{"key":"2998_CR322","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"2998_CR323","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","volume":"54","author":"H Easwaran","year":"2014","unstructured":"Easwaran, H., Tsai, H.-C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell. 54, 716\u2013727 (2014).","journal-title":"Mol. Cell."},{"key":"2998_CR324","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284\u20131300.e21 (2017).","journal-title":"Cell"},{"key":"2998_CR325","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G. & Postel-Vinay, S. Combining epigenetic drugs with other therapies for solid tumours \u2014 past lessons and future promise. Nat. Rev. Clin. Oncol. 17, 91\u2013107 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2998_CR326","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"2998_CR327","doi-asserted-by":"publisher","first-page":"e003237","DOI":"10.1136\/jitc-2021-003237","volume":"9","author":"SA Nalawade","year":"2021","unstructured":"Nalawade, S. A. et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J. Immunother. Cancer 9, e003237 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR328","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","volume":"11","author":"P De Cicco","year":"2020","unstructured":"De Cicco, P., Ercolano, G. & Ianaro, A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front. Immunol. 11, 1680 (2020).","journal-title":"Front. Immunol."},{"key":"2998_CR329","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/eji.201040895","volume":"40","author":"J Youn","year":"2010","unstructured":"Youn, J. & Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40, 2969\u20132975 (2010).","journal-title":"Eur. J. Immunol."},{"key":"2998_CR330","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","volume":"6","author":"R Jitschin","year":"2018","unstructured":"Jitschin, R. et al. CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells. J. Immunother. Cancer 6, 116 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR331","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645242","volume":"12","author":"GO Rangel Rivera","year":"2021","unstructured":"Rangel Rivera, G. O. et al. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Front. Immunol. 12, 645242 (2021).","journal-title":"Front. Immunol."},{"key":"2998_CR332","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1042\/CS20190587","volume":"133","author":"S Cheng","year":"2019","unstructured":"Cheng, S. et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPAR\u03b3-mediated pathway in bladder cancer. Clin. Sci. 133, 1745\u20131758 (2019).","journal-title":"Clin. Sci."},{"key":"2998_CR333","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","volume":"30","author":"P Cheng","year":"2022","unstructured":"Cheng, P. et al. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma. Mol. Ther. 30, 2315\u20132326 (2022).","journal-title":"Mol. Ther."},{"key":"2998_CR334","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016059","volume":"13","author":"R Fan","year":"2022","unstructured":"Fan, R. et al. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Front. Immunol. 13, 1016059 (2022).","journal-title":"Front. Immunol."},{"key":"2998_CR335","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004167","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang, L., Chard Dunmall, L. S., Cheng, Z. & Wang, Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J. Immunother. Cancer 10, e004167 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2998_CR336","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara, Y. et al. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol. Immunother. 72, 1285\u20131300 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR337","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1182\/blood-2017-01-761585","volume":"129","author":"S Brandau","year":"2017","unstructured":"Brandau, S. & Hartl, D. Lost in neutrophil heterogeneity? CD10!. Blood 129, 1240\u20131241 (2017).","journal-title":"Blood"},{"key":"2998_CR338","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1164\/rccm.201204-0636OC","volume":"186","author":"P-H Feng","year":"2012","unstructured":"Feng, P.-H. et al. CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non\u2013small cell lung cancer. Am. J. Respir. Crit. Care Med. 186, 1025\u20131036 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2998_CR339","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cytob.21206","volume":"88","author":"V Damuzzo","year":"2015","unstructured":"Damuzzo, V. et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytom. B Clin. Cytom. 88, 77\u201391 (2015).","journal-title":"Cytom. B Clin. Cytom."},{"key":"2998_CR340","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-019-02302-2","volume":"68","author":"L Cassetta","year":"2019","unstructured":"Cassetta, L. et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol. Immunother. 68, 687\u2013697 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR341","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00011-023-01737-9","volume":"72","author":"K Ganesh","year":"2023","unstructured":"Ganesh, K. & Joshi, M. B. Neutrophil sub-types in maintaining immune homeostasis during steady state, infections and sterile inflammation. Inflamm. Res. 72, 1175\u20131192 (2023).","journal-title":"Inflamm. Res."},{"key":"2998_CR342","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2016-01-688887","volume":"127","author":"C Silvestre-Roig","year":"2016","unstructured":"Silvestre-Roig, C., Hidalgo, A. & Soehnlein, O. Neutrophil heterogeneity: Implications for homeostasis and pathogenesis. Blood 127, 2173\u20132181 (2016).","journal-title":"Blood"},{"key":"2998_CR343","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","volume":"40","author":"C Silvestre-Roig","year":"2019","unstructured":"Silvestre-Roig, C., Fridlender, Z. G., Glogauer, M. & Scapini, P. Neutrophil diversity in health and disease. Trends Immunol. 40, 565\u2013583 (2019).","journal-title":"Trends Immunol."},{"key":"2998_CR344","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2019.00346","volume":"10","author":"R Grieshaber-Bouyer","year":"2019","unstructured":"Grieshaber-Bouyer, R. & Nigrovic, P. A. Neutrophil heterogeneity as therapeutic opportunity in immune-mediated disease. Front. Immunol. 10, 346 (2019).","journal-title":"Front. Immunol."},{"key":"2998_CR345","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1111\/all.13829","volume":"74","author":"Q Guan","year":"2019","unstructured":"Guan, Q. et al. Myeloid-derived suppressor cells: roles and relations with TH2, Th17, and treg cells in asthma. Allergy 74, 2233\u20132237 (2019).","journal-title":"Allergy"},{"key":"2998_CR346","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568362","volume":"11","author":"L Yan","year":"2020","unstructured":"Yan, L. et al. The immunoregulatory role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis. Front. Immunol. 11, 568362 (2020).","journal-title":"Front. Immunol."},{"key":"2998_CR347","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41423-019-0271-8","volume":"16","author":"J Ji","year":"2019","unstructured":"Ji, J. et al. MDSCs: friend or foe in systemic lupus erythematosus. Cell. Mol. Immunol. 16, 937\u2013939 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"2998_CR348","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1053\/j.gastro.2008.06.032","volume":"135","author":"LA Haile","year":"2008","unstructured":"Haile, L. A. et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 135, 871\u2013881.e5 (2008).","journal-title":"Gastroenterology"},{"key":"2998_CR349","doi-asserted-by":"publisher","first-page":"1021634","DOI":"10.3389\/fimmu.2022.1021634","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao, F., Gong, W., Song, J., Shen, Z. & Cui, D. The paradoxical role of MDSCs in inflammatory bowel diseases: from bench to bedside. Front. Immunol. 13, 1021634 (2022).","journal-title":"Front. Immunol."},{"key":"2998_CR350","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12272-019-01165-6","volume":"42","author":"S-M Park","year":"2019","unstructured":"Park, S.-M. & Youn, J.-I. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch. Pharm. Res. 42, 560\u2013566 (2019).","journal-title":"Arch. Pharm. Res."},{"key":"2998_CR351","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00262-019-02472-z","volume":"69","author":"C Bergenfelz","year":"2020","unstructured":"Bergenfelz, C., Rox\u00e5, A., Mehmeti, M., Leandersson, K. & Larsson, A.-M. Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. Cancer Immunol. Immunother. 69, 435\u2013448 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"2998_CR352","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0541-z","volume":"17","author":"JK Bailur","year":"2015","unstructured":"Bailur, J. K., Gueckel, B., Derhovanessian, E. & Pawelec, G. Presence of circulating Her2-reactive CD8\u2009+\u2009T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. 17, 34 (2015).","journal-title":"Breast Cancer Res."},{"key":"2998_CR353","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3390\/ijms25052985","volume":"25","author":"J Arshad","year":"2024","unstructured":"Arshad, J. et al. Myeloid-derived suppressor cells: therapeutic target for gastrointestinal cancers. Int. J. Mol. Sci. 25, 2985 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2998_CR354","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin, R. P. et al. Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin. Cancer Res. 29, 1209\u20131219 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR355","doi-asserted-by":"publisher","first-page":"175883592513493","DOI":"10.1177\/17588359251349321","volume":"17","author":"JSW Borgers","year":"2025","unstructured":"Borgers, J. S. W. et al. Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. Ther. Adv. Med. Oncol. 17, 17588359251349321 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2998_CR356","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","volume":"299","author":"WF Regine","year":"2008","unstructured":"Regine, W. F. et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299, 1019\u20131026 (2008).","journal-title":"JAMA"},{"key":"2998_CR357","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115\u2013124 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2998_CR358","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.22.02623","volume":"41","author":"RJ Motzer","year":"2023","unstructured":"Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 41, 1965\u20131971 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2998_CR359","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-14-1716","volume":"21","author":"JA Califano","year":"2015","unstructured":"Califano, J. A. et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 30\u201338 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR360","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","volume":"22","author":"JA Sparano","year":"2004","unstructured":"Sparano, J. A. et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern cooperative oncology group trial E2196. J. Clin. Oncol. 22, 4683\u20134690 (2004).","journal-title":"J. Clin. Oncol."},{"key":"2998_CR361","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","volume":"27","author":"MD Hellmann","year":"2021","unstructured":"Hellmann, M. D. et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti\u2013PD-(L)1 therapy. Clin. Cancer Res. 27, 1019\u20131028 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2998_CR362","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2024.42.16_suppl.9508","volume":"42","author":"SP Patel","year":"2024","unstructured":"Patel, S. P. et al. Safety and efficacy of first-in-class CXCR1\/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti\u2013PD-1 therapy. J. Clin. Oncol. 42, 9508\u20139508 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2998_CR363","doi-asserted-by":"publisher","first-page":"e000249","DOI":"10.1136\/bmjonc-2023-000249","volume":"3","author":"A Naing","year":"2024","unstructured":"Naing, A. et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. 3, e000249 (2024).","journal-title":"BMJ Oncol."},{"key":"2998_CR364","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2998_CR365","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. OncoImmunology 4, e994446 (2015).","journal-title":"OncoImmunology"},{"key":"2998_CR366","doi-asserted-by":"publisher","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","volume":"9","author":"H Qin","year":"2021","unstructured":"Qin, H. et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J. Immunother. Cancer 9, e003149 (2021).","journal-title":"J. Immunother. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02998-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:02:57Z","timestamp":1788901377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02998-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":366,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02998-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"378"}}